Sanofi
https://www.sanofi.com//
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sanofi
MorphoSys, After Its Commercial Debut, Looks To The Next Growth Phase
Interview: CEO Jean-Paul Kress talked to Scrip about the US launch of Monjuvi, commercial expansion and the aspiration to build a European biotech that can compete in the big leagues.
PDUFA VII Could Increase Transparency Of REMS Release Process
Proposed commitment letter language included a look at eliminating REMS, potentially to more clearly outline the process.
Finance Watch: Investors Launch New SPACs After Initial Deals
EcoR1 and Casdin/Corvex took their second and third special purpose acquisition corporations public. Also, Ionis sold notes to buy back older notes and fund operations as it cut 70% of Akcea’s staff. In venture capital, ValenzaBio raised $70m and RA boosted Metagenomi’s series A to $75m.
Higher Medicaid Rebates For Expedited Approvals Offer Modest Savings But Target Growing Concern
As MACPAC moves toward formal recommendations, a CBO analysis finds that differential Medicaid rebates for drugs approved through the accelerated pathway could save the federal government up to $1bn over five years.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
- Vaccines
- Other Names / Subsidiaries
-
- Ablynx N.V.
- Acambis PLC
- Bioverativ Inc. (True North Therapeutics, Inc.)
- BiPar Sciences Inc.
- BMP Sunstone Corporation
- Canderm Pharma Inc.
- Chattem, Inc.
- Connaught Laboratories Ltd.
- Fisons Ltd.
- Fovea Pharmaceuticals, SA
- Genfar S.A.
- Genzyme Corporation
- Groupe Sanofi
- Hoechst Marion Roussel
- Pluromed
- Principia Biopharma Inc. Protein Sciences Corporation
- Rhone-Poulenc Rorer
- Sanofi-Aventis
- Sanofi-aventis Groupe
- Sanofi Pasteur MSD
- Shantha
- Synthorx, Inc. (THOR)
- TargeGen, Inc.
- Thunder Acquisition
- Tidal Therapeutics, Avigen Inc.